An Ermer & Suter PLLC service providing Federal Employees Health Benefits Program and general health benefits law and policy information -- but not legal advice
Thursday, October 26, 2006
Another False Claims Act Settlement
According to a U.S. Justice Department press release, Intermune, a California-based biopharmaceutical manufacturer, agreed to pay the U.S. Government $39.2 million in settlement of Government charges that Intermune caused false claims to be submitted to Medicare, Medicaid, TRICARE, and the FEHB Program based on its illegal promotion of its Actimmune drug for a use -- the treatment of lung scarring -- that the Food and Drug Administration had not approved.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment